[Status of pharmacogenomics and its future role in drug therapy].
Cascorbi
I
I
Abteilung Allgemeine Pharmakologie, Institut für Pharmakologie, Klinikum der Ernst-Moritz-Arndt-Universität Greifswald, Freidrich-Loeffler-Strasse. 23D, 17487 Greifswald. cascorbi@uni-greifswald.de
D001189:Aryl Hydrocarbon Hydroxylases; D001191:Arylamine N-Acetyltransferase / Q000235:genetics; D002986:Clinical Trials as Topic / Q000639:trends*; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D004358:Drug Therapy / Q000639:trends*; D006801:Humans; D008780:Methyltransferases / Q000235:genetics; D006899:Mixed Function Oxygenases / Q000235:genetics; D010597:Pharmacogenetics / Q000639:trends*; D010599:Pharmacokinetics; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000235:genetics
D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D013250:Steroid Hydroxylases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6; D039181:Steroid 16-alpha-Hydroxylase; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D001191:Arylamine N-Acetyltransferase
Stand der Pharmakogenomik und deren zukünftige Rolle für die Arzneitherapie.